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Abstract
Microneedle vaccines mimic several aspects of cutaneous pathogen invasion by targeting antigen
to skin-resident dendritic cells and triggering local inflammatory responses in the skin, which are
correlated with enhanced immune responses. Here we tested whether control over vaccine delivery
kinetics can enhance immunity through further mimicry of kinetic profiles present during natural
acute infections. We report an approach for the fabrication of silk/poly(acrylic acid) (PAA)
composite microneedles composed of a silk tip supported on a PAA base. On brief application of
microneedle patches to skin, the PAA bases rapidly dissolved to deliver a protein subunit vaccine
bolus, while also implanting persistent silk hydrogel depots into the skin for a low-level sustained
cutaneous vaccine release over 1-2 weeks. Use of this platform to deliver a model whole-protein
vaccine with optimized release kinetics resulted in >10-fold increases in antigen-specific T-cell
and humoral immune responses relative to traditional parenteral needle-based immunization.
1. Introduction
Microneedle skin patches represent an attractive technology for non-invasive transcutaneous
delivery of vaccines, exploiting the accessibility and proven immune-competence of the skin
for enhanced immunity. The delivery of vaccines to the skin, a tissue densely populated with
antigen presenting cells and inherently adapted to respond to invading pathogens, has been
shown in many contexts to improve the potency of immunity compared with traditional
parenteral immunization approaches targeting less immunogenic tissues such as muscle
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(reviewed in [1]). Microneedle vaccination has in many cases also outperformed hypodermic
needle-based delivery to the skin, suggesting the importance of factors relating to
microneedle delivery itself, such as the inflammatory state generated by micron-scale
wounding following microneedle insertion.[2, 3] Unrelated studies have begun to reveal the
importance of antigen and adjuvant delivery kinetics in the developing immune response,
both within the context of vaccination and in natural responses to infection.[4-7] For
example, the magnitude, functionality, and phenotype of CD8+ T-cell responses can be
shaped by immunizations where antigen or adjuvant delivery kinetics are controlled over
multi-week periods, with persistent antigenic and inflammatory signals eliciting stronger
responses than transient bolus vaccine exposure.[4, 5] These findings are consistent with
known differences in the natural immunity generated against transient vs. persistent
pathogens, indicating specific mechanisms of immunity that may be exploited through
engineered kinetics to yield greater vaccine efficacy.
We have recently begun to explore the combination of these two approaches for enhancing
immunogenicity, through the design and testing of microneedle platforms capable of
controlling the kinetics of vaccine delivery in vivo. Microneedle patches composed of a
single monolithic polymer phase require that patches remain on the skin for prolonged time
periods to achieve extended drug release. Conversely, our previous composite microneedle
structures, based on solid biodegradable poly(lactide-co-glycolide) (PLGA) polymer tips
supported on a water-soluble poly(acrylic acid) (PAA) base rapidly disintegrate upon skin
application, implanting the solid polymer tips into the skin following a brief ~5 min
application.[8] The implanted polymer tips can subsequently provide sustained release of
encapsulated cargos over a tunable period of days to weeks. In these previous studies,
vaccination utilizing PLGA/PAA composite microneedles implanting persistent polymer
depots for slow cutaneous release of adjuvant following bolus antigen delivery yielded
improved proliferation, stronger antigen-dependent cytokine secretion, and altered memory
phenotypes in assays of CD8+ T cell immunity.[8] Here we have expanded upon this concept
through the design of a microneedle system based on silk protein, creating implantable
hydrogel microneedle matrices for efficient vaccine loading and highly tailorable vaccine
release kinetics in vivo. Unlike PLGA, loading of biomolecules in silk protein matrices is a
simple one-step process. Silk has previously been used for high-density loading of sensitive
biomolecules into non-immunogenic hydrogels under mild aqueous processing conditions,
which subsequently release entrapped cargo for extended periods of time.[9, 10] Recent work
has demonstrated the ability of dried silk hydrogels to form dense microneedle structures
that can be inserted into murine skin ex vivo.[11, 12] The additional capacity for effective
stabilization of vaccines and drugs in silk at room temperature offers an attractive
opportunity to formulate vaccines which could avoid the cold chain, thus making vaccines
more inexpensive and readily available.[13]
Here we sought to combine the advantages of our implantable-tip composite microneedle
design with the beneficial properties of silk as a controlled release matrix for entrapped
proteins, and explored the ability of silk/PAA composite microneedles to regulate the
kinetics of vaccine delivery in skin with the goal of mimicking patterns of antigen and
inflammatory signal exposure during natural infections. Composite microneedles were
loaded with an adjuvanted whole-protein subunit vaccine encapsulated in either PAA
pedestals (providing a rapid initial bolus of vaccine release), or silk tips, which mediate
slow/sustained vaccine release over time. We observed dramatic variations in the strength of
antigen-specific T cell responses dependent upon the temporal patterns of bolus and
extended vaccine delivery programmed through materials engineering of the silk-composite
structure. Combined with the recently demonstrated room temperature stability of vaccines
embedded in silk,[13] this controlled-release microneedle platform has the potential to
combine three important features of next-generation vaccines for use in the developing
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world: (i) needle-free delivery, (ii) inexpensive long-term room temperature storage without
the need for a ‘cold chain’, and (iii) effective single-dose immunization providing potent
immunological memory. Additionally, we have confirmed through these studies the
potential for engineering optimal immune responses through programmed vaccine release
kinetics, an important finding supporting the future use of advanced drug delivery
approaches in the progression of vaccine research.
2. Materials and Methods
2.1. Silk fibroin solution preparation
Cocoons of Bombyx mori silkworm silk were purchased from Aurora Silk (Portland, OR).
All other chemicals were purchased from Sigma-Aldrich (St. Louis, MO) and used as
received. Silk fibroin was prepared from cocoons as previously described.[14] Briefly,
cocoons were boiled for 40 min in a solution of 0.02 M sodium carbonate and then rinsed
thoroughly with deionized water to extract the glue-like sericin protein. After drying, the
extracted silk was dissolved in 9 M lithium bromide solution at 60°C for 4 hours, and
subsequently the salt was removed by dialysis against deionized water using a Slide-a-Lyzer
dialysis cassette (Pierce, Rockford, IL) for 48 hours, changing the water regularly at least six
times. The resulting solution was centrifuged twice (~12,700 rcf) at 4°C for 20 min to
remove impurities and the aggregates that formed during dialysis. The supernatant was
stored at 4°C and filtered through a 450 nm syringe filter prior to use. The final
concentration of silk fibroin solution was determined by weighing the residual solid of a
known volume of solution after drying.
2.2. Fabrication of Silk/PAA Microneedle Arrays
PDMS microneedle molds (Sylgard 184, Dow-Corning, Midland, MI) were prepared using a
Clark-MXRCPA-2010 laser micromachining instrument (VaxDesign Inc., Orlando, FL).
Soluble ovalbumin (OVA, Worthington, Lakewood, NJ) and polyI:C (Invivogen, San Diego,
CA) were combined with aqueous silk solutions (8% w/v) to give the desired immunogen
concentration (generally ~5 mg/ml OVA, 0.5 mg/ml polyI:C). PDMS molds were then
treated with O2 plasma before addition of silk-vaccine formulations to the mold surface by
pipette. Molds were centrifuged for 30 minutes at rcf ≈ 450 and excess silk-vaccine solution
was removed from the mold surface for potential reuse. Molds containing silk-vaccine were
then dried at 25°C for 12 hours and treated with 9:1 (v/v) methanol for 5 minutes or left
untreated. Polyacrylic acid (PAA, 250 kDa, 35%) was then added to soluble OVA and
polyI:C at the desired concentrations (generally ~1 mg/ml OVA, ~0.1 mg/ml polyI:C) and
mixed well. PAA pedestals were then formed through addition of 35% PAA to the mold
surface, followed by centrifugation (30 min, rcf ≈ 450) and drying at 25°C (48 h on the
benchtop, followed by 2–14 days under desiccation), before removal. All microneedles were
stored under desiccation at 25°C for at least 2 months prior to use. Microneedle arrays were
characterized by optical and confocal microscopy using a Leica DMXR and a Zeiss LSM
510 respectively. Total vaccine loading was determined using fluorescently labeled OVA as
described below. PolyI:C loading was determined similarly following elution into PBS using
a ribogreen RNA detection kit (Invitrogen) to determine the loaded RNA concentration.
2.3. In vitro Vaccine Release
Silk implant release was characterized in vitro through brief (< 30 s) exposure of fabricated
arrays to deionized water. Implants were then collected through centrifugation and washed
before application of aqueous suspensions to glass coverslips. After drying, implants were
imaged by SEM using a JEOL 6700F FEG-SEM.
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To differentiate the release kinetics of OVA loaded in PAA or silk and to evaluate the effect
of methanol treatment on release profiles, in vitro OVA release experiments were performed
by immersing silk/PAA composite microneedles in PBS buffer at pH 7.4 and 37±0.5°C.
Dried silk tips in PDMS were fabricated as described above with or without treatment in 9:1
(v/v) methanol:water solution for 5 min prior to PAA addition. Three experimental groups
(n = 4 for each group) were designed: AlexaFluor 555 labeled ovalbumin (AF555-OVA)
loaded in PAA, AlexaFluor 647 labeled ovalbumin (AF647-OVA) loaded in non-treated silk
tips, AF647-OVA loaded in methanol-treated silk tips. For AF555-OVA release from the
PAA portion of composite microneedles, 1 ml aliquots were removed from a 10 ml volume
release bath at predetermined time points and replaced with 1ml of fresh pre-warmed PBS.
For AF647-OVA release from the untreated or methanol-treated silk portion, microneedles
were transferred between 0.5 ml aliquots of fresh pre-warmed PBS at pre-set time points.
The concentration of AF555-OVA and AF647-OVA in each of the release samples was
quantified by fluorescence spectroscopy (M200 Pro, Tecan, Mannedorf, Switzerland). At
each time point, samples were loaded in triplicate and the averaged reading was taken for
further quantification.
2.4. In vivo Microneedle Application and Vaccine Release
All animal studies were approved by the MIT IUCAC and animals were cared for in the
USDA-inspected MIT Animal Facility under federal, state, local, and NIH guidelines for
animal care. Microneedle application experiments were performed on anesthetized C57BL/6
mice (Jackson Laboratories, Bar Harbor, ME) at the flank or dorsal ear skin. Skin was rinsed
briefly with PBS and dried before application of microneedle arrays by gentle pressure.
Following application, mice were euthanized at subsequent time points and the application
site was dissected. Treated skin and applied microneedle arrays were imaged by confocal
microscopy to assess transcutaneous delivery of silk implants. In some cases, treated skin
was excised and fixed in 3.7% formaldehyde for 18 h, then incubated in 30% sucrose/PBS
for 2 h before embedding in optimal cutting temperature medium (OCT, Tissue-Tek) for
histological sectioning on a cryotome. Histological sections were then imaged using
confocal microscopy. Live whole animal imaging was performed using a Xenogen IVIS
Spectrum (Caliper Life Sciences, Hopkinton, MA) on anesthetized mice. For luminescent
imaging of myeloperoxidase (MPO)-dependent oxidative burst, luminol sodium salt (Santa
Cruz Biotech, Santa Cruz, CA) was administered i.p. (250 mg kg-1) before imaging.
Fluorescence/luminescence data was processed using region of interest (ROI) analysis with
background subtraction and internal control ROI comparison to untreated skin using the
Living Image 4.0 software package (Caliper).
2.5. Immunizations
C57Bl/6 mice (5/group) were immunized on day 0 with 9 μg ovalbumin and 150 ng polyI:C
by intradermal (i.d.) injection (15 μL in the dorsal caudal ear skin) or by microneedle array
(5 min application). Microneedles contained ~98% of the total vaccine dose in the PAA
fraction, with the remaining 2% in the silk implant. Silk implants were either left untreated
or cross-linked with methanol as previously described to give differential vaccine release
kinetics. In some cases microneedles were fabricated to contain vaccine in only silk
implants, or otherwise in only the PAA pedestal. Animals vaccinated by i.d. injection
received an identical boost on day 28. Mice were then mock challenged on day 77 with 10
μg pCl-neo-sOVA (pOVA, Addgene, Cambridge, MA) encoding soluble OVA, by
intramuscular (i.m.) injection (25 μl, split between both quadriceps).
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2.6. In vivo Murine Immunogenicity
Frequencies of OVA-specific CD8+ T-cells and their phenotypes elicited by immunization
were determined by flow cytometry analysis of peripheral blood mononuclear cells at
selected time points following staining with DAPI (to discriminate live/dead cells), anti-
CD8α , anti-CD44, anti-CD62L, (BD Biosciences, San Jose, CA), and phycoerythrin-
conjugated SIINFEKL/H-2Kb peptide-MHC tetramers (Beckman Coulter, Indianapolis, IN).
To assess the functionality of primed CD8+ T-cells, peripheral blood mononuclear cells
were stimulated ex vivo with 10 μg/mL OVA-peptide SIINFEKL for 6 h with Brefeldin-A
(Invitrogen, San Diego, CA), fixed, permeabilized, stained with anti-IFNγ, anti-TNFα , and
anti-CD8α (BD Biosciences), and analyzed by flow cytometry. Anti-ovalbumin or anti-silk
IgG, IgG1, IgG2C, and IgM titers, defined as the dilution of sera at which 450 nm OD
reading was 0.25, were determined by ELISA analysis of sera from immunized mice. To
measure avidity index, ELISA was performed after 10 minute exposure of bound serum to
6M urea, to strip weakly bound immunoglobulins.[15] IgG avidity index was calculated as
the ratio of measured titer without urea treatment to titer measured with urea treatment.
3. Results
3.1. Fabrication of Silk-PAA Composite Microneedles
We recently reported a strategy for the fabrication of composite microneedles based on PAA
and PLGA for microneedle-mediated implantation of solid PLGA micro-tips or
microspheres in skin.[8] Here we adapted this approach to create microneedles bearing a
solid silk tip supported by a PAA pedestal, intended to rapidly dissolve in cutaneous tissue
fluids following needle insertion, releasing silk tips for retention in the skin following
microneedle patch removal. To fabricate these structures, we first generated PDMS molds
bearing square pyramidal micro-scale cavities across their surface using laser ablation as
previously described (Figure 1a, step 1).[16] We then surface-treated the molds with O2
plasma to generate a hydrophilic surface and facilitate infiltration of the mold cavities by the
silk-vaccine solution. Silk fibroin protein was co-dissolved in aqueous solution with
ovalbumin protein (OVA, a model antigen) and the TLR-3 agonist polyI:C, a potent double-
stranded RNA adjuvant for stimulating anti-viral immune responses.[17] This solution was
added to plasma-treated molds and infiltration of the mold cavities was further completed
through centrifugation (Figure 1a, step 2). After removing excess silk-vaccine solution, silk-
filled molds were allowed to dry at room temperature for 12 hr to produce hardened silk
hydrogel tips within the PDMS molds (Figure 1a, step 3).[11, 12] Silk protein is known to
undergo increases in crystallinity due to the formation of beta sheets upon exposure to
methanol, effectively producing physical crosslinks within silk matrices; this results in
lowered diffusivity of drug, and prolonged cargo release from rehydrated silk hydrogels.[14]
Here, we exposed solidified silk tips to methanol by pipetting solvent onto the mold surface,
to enhance crystallite formation and retard release of encapsulated vaccine from silk tip
implants following implantation in vivo (Figure 1a, step 3). Following methanol treatment,
we added vaccine-loaded aqueous PAA solutions carrying co-dissolved OVA and polyI:C to
the mold surface and again performed centrifugation to compact the PAA into the mold
cavities, forming complete PAA pedestal structures (Figure 1a, step 4). Microneedles were
then dried in the mold at room temperature for several days and placed under vacuum to
complete the drying process before removal and storage under vacuum at 25°C (Figure 1a,
step 5). This process reliably produced arrays of composite pyramidal microneedles 550μm
in height and 250 μm in width at the base ( 586±7 μm center to center distance, 4.7±0.6 μm
tip radius) bearing a tip-pedestal structure where vaccine-containing silk hydrogel tips were
supported by vaccine-loaded PAA pedestals (Figure 1b). This structure was readily visible
by optical microscopy imaging of microneedles fabricated with Alexafluor 647-labeled
OVA (AF647-OVA) and Alexafluor 555-labeled OVA (AF555-OVA) loaded within the silk
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tip and PAA pedestal, respectively (Figure 1b). We further confirmed this needle
microstructure using confocal microscopy to detect the localization of the vaccine cargo
within the tip or pedestal of the resulting microneedles. This analysis revealed AF647-OVA
restricted to the silk tip of each microneedle with AF555-OVA signal observed only in the
PAA pedestal (Figure 1c). Given our previous results with similar PLGA/PAA systems, we
expected that this composite structure would allow for effective cutaneous insertion of the
hardened composite microneedles, where exposure to interstitial fluids would rapidly
dissolve the PAA pedestals releasing the silk tips, which would remain implanted in the skin
following removal of the array backing.[8]
3.2. In vitro characterization of silk tip release and vaccine cargo delivery
To test our expectation that composite silk/PAA microneedles would rapidly release silk tips
upon exposure to tissue fluids in vivo, we exposed microneedle arrays to deionized water in
vitro for short periods of time to observe PAA dissolution and silk tip release. Here we
visually observed rapid and complete separation of silk tips from PAA composite
microneedle arrays after only 30 seconds of immersion. We then collected the separated silk
tips by centrifugation and imaged them using SEM to observe their structure. Collected tips
maintained their pyramidal geometry with dimensions consistent with the molds used in
their fabrication (Figure 1d). Further high magnification SEM imaging of released tips
revealed a nano-porous network structure consistent with bundling of silk proteins to form a
self-assembled network structure (Figure 1d).
To confirm the ability of composite silk/PAA microneedles to provide control over vaccine
release profiles, we fabricated microneedle arrays containing AF647-OVA loaded in the silk
needle tips or AF555-OVA in the PAA pedestals. Silk tips were either left untreated or
treated with methanol as before to introduce additional cross-linking into the silk hydrogels.
We then immersed each array in phosphate buffered saline pH 7.4 (PBS) at 37°C and
collected fractions of the solution at subsequent time points to measure the release of
encapsulated OVA protein by fluorescence spectroscopy. Consistent with expectations,
AF555-OVA loaded into the PAA phase was rapidly dispensed from dissolving pedestals,
with complete release over the course of only 2 hours (Figure 1e). Conversely, AF555-OVA
loaded into silk hydrogel tips was released more slowly with kinetics further modulated by
methanol exposure during fabrication. For microneedles bearing untreated silk tips, AF647-
OVA exhibited a burst release of ~70% over the course of 2 hours with sustained release of
the remaining 30% over the next 5-6 days (Figure 1e). Delivery from methanol-treated silk
was further delayed with only 25% burst release over 2 hours, and sustained near-zero order
release of the remaining 75% over the course of 8-12 days (Figure 1e). Thus, the
combination of rapidly dissolving PAA with the slow swelling of silk hydrogels permits the
kinetics of vaccine release to be varied over a wide range, spanning from tens of seconds to
more than a week.
3.3. Composite Microneedles Rapidly Implant Silk Tips to Form Cutaneous Vaccine Depots
In Vivo
We previously demonstrated that composite PLGA/PAA microneedles penetrate skin, and
prior work has also shown the ability of solid silk microneedles to effectively insert into
murine skin.[11] To confirm the ability of composite silk/PAA microneedles to effectively
penetrate the skin, we fabricated microneedles encapsulating AF647-OVA and AF555-OVA
in the silk and PAA microneedle phases, respectively, and applied these arrays to the skin of
C57Bl/6 mice for 5 minutes. Confocal imaging of microneedle arrays before and after
application revealed complete loss of both silk- and PAA-associated OVA fluorescent signal
from the length of each microneedle following 5 min insertion in skin (Figure 2a). Confocal
imaging on excised skin or skin histological sections where patches were applied revealed
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overlaid punctate fluorescent signal from AF647-OVA and AF555-OVA at individual sites
of microneedle insertion indicating the effective delivery of both silk- and PAA-loaded
materials upon microneedle penetration into the cutaneous space (Figure 2b-c). In these
images microneedles were observed to insert several hundred microns below the skin
surface in the epidermal space, consistent with previous demonstrations of microneedle
delivery.[3, 8, 18] Three-dimensional rendering of confocal z-stacks to visualize the depth of
fluorescent OVA delivery showed fluorescent signals from AF647- and AF555-OVA from
silk and PAA respectively, extending several hundred microns below the skin surface at
sites of microneedle insertion (Supplementary Figure 1). Further, similar to our previous
results, we visually observed healing of the microscopic skin defects created during
microneedle application within 1 day of treatment.[8] Together these results confirm the
ability of silk/PAA microneedles to effectively insert into murine skin, with rapid
dissolution of the PAA pedestal upon exposure to skin fluids to leave behind vaccine-loaded
silk hydrogels.
To simplify the fabrication scheme in these proof-of-concept studies, active agent was
contained within the entire PAA fraction of the composite microneedle array, including the
patch backing as well as the individual needle pedestals. Thus, although Figure 2a shows
that active agent from the needle pedestals is completely lost during application, an effective
efficiency of delivery accounting for the entire PAA phase including the patch backing was
calculated to be 3%. This low overall efficiency of delivery could be corrected through a
multi-step PAA addition during fabrication to generate patches with active agent loaded
only into the needle pedestals, thus eliminating wasted material contained in the patch
backing. However, for these proof-of-concept studies meant to explore the fundamental
impact of prolonged delivery from implanted hydrogels, we chose to employ the simpler
single-step fabrication approach. Importantly, all reported vaccine dosages below account
for the amount of vaccine actually delivered into the skin from the PAA phase.
3.4. Cutaneous Silk Implants Control Vaccine Release Kinetics In Vivo
We next tested whether microneedle-delivered vaccine release in vivo could be programmed
during array fabrication. Similar to previous experiments, we fabricated microneedles
containing AF647-OVA and AF555-OVA in the silk or PAA needle fraction respectively,
and applied these to the auricular skin of anesthetized C57Bl/6 mice. For comparison to
parenteral administration, we performed intradermal (i.d.) injection of dose-matched soluble
fluorescent vaccine formulations in the dorsal ear skin. We then used whole-animal
fluorescence imaging to monitor the persistence of the OVA fluorescent signal at the
treatment site and determine the release characteristics of injected or microneedle-delivered
vaccine in vivo. Fluorescence imaging revealed the rapid loss of AF555-OVA signal in all
test groups, indicating the clearance of soluble OVA from the treatment site within 24 hours
of delivery either by i.d. injection, or from the PAA phase of composite microneedles
(Figure 2d-e). Clearance of AF647-OVA was similarly rapid in the case of i.d. injection.
Conversely, AF647-OVA encapsulated in silk-implants was retained at the treatment site for
days to weeks following microneedle treatment, depending on whether methanol treatment
was performed during fabrication to induce additional silk hydrogel beta sheet formation
(Figure 2d-e). Animals treated with silk/PAA microneedles without methanol treatment
showed nearly linear clearance of silk-loaded AF647-OVA over the course of 4 days
following treatment. In the case of microneedles pretreated with methanol, AF647-OVA
fluorescent signal was detectable at the treatment site for >16 days following array
application (Figure 2d-e). Notably, distinct from the in vitro release pattern, these in vivo
antigen release profiles showed no burst release. These results indicate the ability of
microneedle-delivered silk tip implants to control the rate of vaccine release in vivo with a
kinetic profile dependent on methanol treatment during fabrication.
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3.5. Microneedle Vaccine Release Kinetics Determine the Strength of Cellular Immunity
Many natural infections are characterized by an initially abundant microbe burden lasting a
few days, which is predominantly eliminated by the initial immune response. However, in
many “acute” infections, this initial elimination of microbes is followed by a delayed
clearance of residual low levels of the pathogen that persist for a more prolonged period
prior to complete eradication.[19-23] Thus the natural immune system is frequently exposed
to a large pathogenic bolus of antigenic and inflammatory stimuli, followed by a prolonged
low-level exposure which can persist for days to months following acute infection. Given
that such kinetic patterns in natural infection are often associated with profound T-cell
responses and robust immune memory, we sought to determine whether tailoring vaccine
exposure kinetics using silk/PAA microneedles to mimic this natural progression of
infection would impact vaccine immunogenicity relative to bolus injection or bolus
microneedle delivery. To mimic the adjuvant/inflammation kinetics described above for
acute infection, microneedles were fabricated with the vaccine dose split (98% and 2%)
between the PAA and silk fractions with or without methanol pretreatment (MN PAA(98)/
Silk(2) and MN PAA(98)/MeOH-Silk(2)). The single-step fabrication approach for the silk
tips used here, where the microneedle cavities are filled with silk/vaccine solution and
simply dried to form the silk tips, limited the capacity of the silk matrix to a theoretical
maximum of only ~2-4 μg of antigen loaded in the silk tips (total per patch). Since we could
not generate PAA(0)/silk(100) arrays that would match the total vaccine dose of the
PAA(98)/silk(2) microneedles and keep the fabrication process identical, we instead
employed two alternative controls: microneedles were fabricated with either 98% of the
vaccine dose in the PAA fraction (MN PAA(98)/Silk(0)) or 2% of the dose in the silk
fraction (MN PAA(0)/Silk(2)), testing whether either of the vaccine partitions of the main
test cases could replicate the response of the combined bolus+sustained release
microneedles. The skin patches were further stored at room temperature under desiccation
for at least 2 months prior to use, to establish their ability to eliminate cold storage
requirements for the vaccine.
We then vaccinated mice with 9 μg OVA and 150 ng polyI:C either by i.d. injection at the
dorsal ear site (i.d. Inj.) or by microneedle administration as before. To monitor cellular
immunity we measured OVA-specific CD8+ T-cell proliferation in peripheral blood using
SIINFEKL/H-2Kb peptide-MHC tetramers (SIINFEKL is the immunodominant peptide
epitope of OVA). This analysis revealed that i.d.-injected vaccines elicited extremely weak
antigen-specific CD8+ T-cell responses, with minimal expansion of OVA-specific cells over
4 weeks following a single immunization (~1% of CD8+ T cells, Figure 3a-b). Microneedles
carrying a fraction of the vaccine dose solely in the PAA or solely in the silk phase induced
stronger CD8+ T-cell proliferation, reaching a few percent tetramer+ CD8+ T-cells by 14
days following immunization (Figure 3a-b). Interestingly, for the two microneedle groups
containing a small fraction of the vaccine dose in the silk tips and the bulk of the vaccine in
the PAA phase, the T-cell response was stronger than each of the prior groups (Figure 3a-c).
Strikingly, methanol-treated silk tip implants that provided a sustained low dose of the
vaccine over 2 weeks after the initial bolus PAA release resulted in dramatic increases in the
frequency of tet+ CD8+ T-cells compared to the other vaccination regimens (Figure 3a-c).
Two weeks following microneedle patch application, SIINFEKL-specific CD8+ T-cells
expanded to 10-20% of all CD8+ T cells in this group. To test the functionality of these
expanded T-cells, we restimulated peripheral blood mononuclear cells (PBMCs) on day 14
ex vivo with SIINFEKL and assessed production of the inflammatory cytokines IFN-γ and
TNF-α using intracellular staining. Flow cytometric analysis revealed high frequencies of
antigen-specific functional cytokine-secreting CD8+ T cells in the case of microneedle
vaccination, while i.d.-injected animals showed only background levels of activation, as
expected from the tetramer-staining analysis (Figure 3d-e and Supplementary Figure 2).
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Sustained low-level vaccine exposure from methanol cross-linked silk tip implants resulted
in significantly higher frequencies of IFN-γ+ and IFN-γ+ TNF-α+ multi-functional T-cells
compared to the other vaccine groups (Figure 3d-e and Supplementary Figure 2). Notably,
the single silk/PAA composite microneedle treatment was able to induce CD8+ T cell
responses of similar magnitude and cytokine secretion capacity as those observed after a
prime + boost regimen administered by i.d. injection (Supplementary Figure 3). These
significant increases in the magnitude of cellular immune responses suggest that both
microneedle delivery and prolonged antigen/adjuvant delivery kinetics can substantially
enhance the strength of the adaptive cellular immune response in transcutaneous
vaccination.
Sustained antigen stimulus has been implicated in controlling memory cell phenotype and
function.[6, 7] Thus, we next compared the memory phenotype of CD8+ T-cells elicited by
single silk/PAA microneedle treatment to prime-boost vaccination administered by i.d.
injection. We observed a significant increase in the frequency of CD44+ CD62L+ central
memory CD8+ T-cells on day 63 following microneedle vaccination compared to injection
(Figure 4a-b). Central memory T-cells have previously been correlated with effective
immunological responses through more rapid recall upon re-exposure to pathogen, and are
thought to be important for long term protection.[24] Finally, we measured the strength of
CD8+ T cell expansion upon recall in vivo with injected OVA-expressing plasmid DNA
(pOVA). Here we observed statistically identical expansion of SIINKEFL reactive,
cytokine-secreting CD8+ T cells 14 days following recall challenge with pOVA in mice
vaccinated once with silk/PAA microneedles or given two i.d. injections, suggesting that a
single immunization by silk/PAA microneedle delivery can provide equivalent T-cell
memory to a prime + boost parenteral vaccine (Figure 4c-e).
3.6. Microneedle Vaccination Gives More Potent and Balanced Humoral Immunity
To evaluate the antibody response elicited by composite silk/PAA microneedles vaccines,
we collected sera from immunized mice on day 21 following a single i.d. injection of
vaccine, MN PAA(98)/Silk(2) vaccination, MN PAA(98)/MeOH-Silk(2), or MN PAA(98)/
Silk(0) vaccination. ELISA measurements of serum titers of OVA-specific IgM, IgG, IgG1,
and IgG2C showed a consistent increase in the serum titers of class-switched OVA-specific
antibodies for microneedle-immunized animals. Microneedle vaccines induced significant
increases in serum titers for anti-OVA IgG, IgG1, and IgG2C, while no difference was
observed for IgM (Figure 5a-d). The effect on “Th1-like” IgG2C antibody responses was
particularly striking, as i.d. injection elicited no OVA-specific IgG2C response, while all
microneedle groups elicited readily detectable IgG2C titers. These results suggest that
microneedle delivery was able to elicit a more potent, Th1/Th2-balanced antibody repertoire
compared to i.d. injection. However, sustained release of antigen from the silk tips was not
required for this strong enhancement of humoral responses, as microneedles carrying
vaccine only in the PAA phase elicited similarly high anti-OVA titers. We also analyzed the
avidity of the elicited IgG responses using urea exposure before ELISA detection to strip
away weakly binding immunoglobulins.[15] This analysis demonstrated significantly
improved IgG avidity for mice receiving microneedle vaccines as compared to i.d. injected
vaccines, with non-methanol treated silk microneedles eliciting the greatest increase in
avidity (Figure 5e). To confirm the low immunogenicity of silk protein used in these studies,
we also measured the presence of silk-specific serum IgG by ELISA. In mice given i.d.
injection or microneedle vaccines, no anti-silk IgG above the background of naïve mice was
detected (Supplementary Figure 4). Together, these results indicate that microneedle
vaccines strongly augment the humoral response relative to traditional syringe injections,
whether the vaccine is released in a bolus or over days to weeks.
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3.7. Cutaneous Silk Implants Give Sustained Local Inflammatory Activation In Vivo
Finally, having shown the ability of composite silk/PAA microneedles to achieve prolonged
vaccine release, we sought to determine whether persistent local inflammation in the case of
MN PAA(98)/MeOH-Silk(2) immunizations might be contributing to the enhanced cellular
immunity observed for these microneedle formulations. To this end, we used whole-animal
luminescent imaging with the chemiluminescent probe luminol to longitudinally measure
myeloperoxidase (MPO)-dependent oxidative flux in locally-recruited inflammatory cells as
an indication of inflammatory activation at the treatment site.[25, 26] This approach has
previously been used to observe recruitment of activated immune cells such as neutrophils
and serves as a general marker for local innate inflammatory responses. Groups of mice
were immunized by i.d. injection of OVA mixed with polyI:C as before, or treated with
microneedles loaded with OVA and polyI:C in both the silk (±MeOH) and PAA fractions.
Luminescent imaging indicated that i.d. injection produced only low-level inflammation at
the treatment site which resolved completely after 4 days (Figure 6a-b). Conversely,
microneedle delivery with either untreated or methanol-treated silk/PAA microneedles
showed a significant burst of inflammation for 3 days following treatment. After 5 days
mice vaccinated with untreated silk showed only background levels of MPO-dependent
chemiluminescence, while methanol treated silk microneedles gave significant luminescent
signal above background on days 4, 5, and 11, suggesting persistent low-level inflammatory
activation in these mice, likely resulting from prolonged release of antigen/adjuvant from the
MeOH-treated silk implants. However, no visible signs of excessive inflammation or tissue
damage were observed in any of the mice in these treatment groups. Further, i.d. injection of
5x excess silk doses alone without adjuvant produced signal similar to i.d. injection alone,
confirming the non-inflammatory nature of purified silk proteins in vivo (data not shown,
reviewed in [9]). Finally, we have previously observed that sustained local delivery of
polyI:C in the skin producing similar levels of luminol-dependent bioluminescent signal
does not lead to measurable production of systemic cytokines, further suggesting the safety
of this approach.[18] Together with the previous in vivo OVA delivery results, this indicates
the ability of silk/PAA microneedles to sustain both antigen exposure and inflammatory
cues from days to weeks following treatment in vivo. This sustained low level of
inflammation combined with continuous antigen delivery is likely a key factor in priming
the potent CD8+ T cell proliferation observed following microneedle vaccination with
methanol cross-linked silk tips.
4. Discussion
The development of novel microneedle structures has yielded impressive progress in the
advancement of effective, safe, and convenient delivery of macromolecules for vaccination
in the skin.[18, 27, 28] These efforts have sought to effectively balance the many critical
features essential for the effective clinical deployment of microneedle patch delivery
systems including (i) suitable mechanical properties, (ii) control over micron-scale needle
geometry and dimensions, (iii) the ability to achieve rapid administration, (iv) effective
encapsulation of sensitive biomolecules, and (v) avoidance of unwanted toxicity (reviewed
in [1]). Here we have demonstrated the fabrication and application of silk/PAA composite
microneedle arrays that are well suited to address each of these design goals. These
structured skin patches can encapsulate fragile protein or nucleic acid vaccine components
in the silk phase, which has previously been demonstrated to protect vaccines in a dried
state; and the microneedles readily penetrated murine skin, providing rapid deposition of
vaccine into the skin over several minutes. Further, composite silk/PAA microneedles
provide robust flexibility in programming vaccine dosage and long-term delivery kinetics
while retaining the ability to provide rapid and simple administration, a feature which we
have shown to be critical for tuning the potency of immunity.
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Previous studies of silk have shown effective loading of sensitive biomolecules including
vaccines into silk matrices for storage at room temperature.[9, 13, 14, 29] This is an attractive
feature that could allow for inexpensive and broader global dissemination of vaccines to
remote areas of the world. Here we confirmed the potential for silk to stabilize subunit
vaccines during room temperature storage, as all silk/PAA microneedles used in these
studies were stored at room temperature for >2 months prior to use. As observed previously,
vaccine components entrapped within the dried PAA matrix are also protected during room
temperature storage without loss of in vivo immunogenicity.[8] Prior studies of silk
microneedles have demonstrated effective methods for fabrication as well as consistent
insertion into murine skin.[11, 12] We have expanded upon these results here to demonstrate a
new approach for silk microneedle fabrication, taking advantage of the controlled release
capacity for silk hydrogels while also improving the practicality of microneedle application
via the releasable tip design. Recently, a similar approach for controlling vaccine release
from microneedles has been described for the dermal implantation of chitosan reservoirs
from poly(lactide) pedestals.[30] These embeddable chitosan microneedles showed control
over week-long protein release resulting in enhanced humoral immune responses, indicating
the potential of this approach for tuning immunity. Here we have exploited the tunability of
silk matrices for regulating vaccine release over days to weeks to demonstrate the impact of
controlling vaccine kinetics on both cellular and humoral immunity.
It is well established that microneedle delivery of vaccines to the skin can enhance immunity
through targeted delivery of antigen and adjuvant to response-governing antigen presenting
cells present at high density within the skin. The physical disruption of the epidermal/dermal
tissues during microneedle delivery is thought to be an important factor in mediating this
enhanced immunity through the recruitment and maturation of antigen presenting cells.[2, 3]
Further, vaccine delivery in the context of epidermal wounding resulting from microneedle
treatment may contribute to a pro-inflammatory microenvironment during cutaneous
vaccination as keratinocytes and other skin-resident cells are known to actively sense and
respond to tissue damage as well as pathogen-associate molecular patterns such as TLR-
agonists.[31] Thus the success of microneedle delivery is likely in part founded in the natural
mechanisms of the skin as a barrier to entry for sensing and responding to natural infections.
Here we have shown that microneedle vaccination can be further enhanced through the
adoption of a similar approach for replicating the natural time course of many diseases in
which acute infection provides initially high levels of antigen and adjuvant stimuli which
then rapidly decrease through immunological mechanisms of pathogen clearance, leading to
long-term low levels of persistent pathogenic stimulus.[19-23] In previous studies the
presence of protein antigen or pathogen-derived genetic material has been observed for
weeks to months in the local site of infection and in draining lymph nodes persisting after
the relatively rapid clearance of infectious agent over the course of several days.[19, 20, 32, 33]
This pattern of sustained antigen exposure following primary clearance of infection has
suggested a potential role for continued antigen/adjuvant stimulation in the development of
primary effector and memory T cell responses, including effects on T cell migration/
homing,[21] establishment of T cell memory phenotypes,[34] and maintenance of effective
long-lived protective T cell responses.[35] Conversely, in some cases, chronic antigen
presentation can lead to dysfunctional memory T cell responses including loss of effector or
proliferative functions or poor long-term survival.[36] This dichotomous development of
either enhanced or defective long-term protective response is thought to be determined in
part by the relative magnitude of sustained antigen exposure with chronic high antigen load
frequently leading to exhausted or anergic phenotypes, while low level exposure commonly
results in maintenance of protective functions. Thus the ability to finely tune the level and
persistence of antigenic or inflammatory cues following microneedle vaccination is likely
critical for eliciting the desired effect on immunogenicity.
DeMuth et al. Page 11
Adv Healthc Mater. Author manuscript; available in PMC 2015 January 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
The silk/PAA composite microneedle system we have developed allows for vaccine delivery
that can be tuned to replicate these timing and dosage features of natural infection through
the combination of bolus vaccine release from rapidly soluble PAA, and extended release
from vaccine-loaded silk depots implanted in the skin upon microneedle application. In our
studies this ability to provide bolus vaccine exposure combined with additional multi-week
low-level delivery was able to drastically improve the proliferative capacity of antigen-
specific T cells, yielding increased levels of peripheral antigen-specific, functionally active
effector CD8+ T cells greatly exceeding those responses generated through injection. These
results indicate the need for both bolus vaccine delivery and sustained release as individual
bolus or sustained release vaccine components gave much weaker responses. Further, the
ability to program the duration of extended release proved important, as multi-week
exposure resulted in 2.8-fold increases in CD8+ T cell responses over shorter multi-day
release profiles. Notably, we observed that CD8+ T cell responses to injected vaccines were
only able to match immunizations with a single application of a microneedle patch following
multiple vaccine doses, suggesting that the combination of microneedle delivery with
programmed vaccine release may eliminate the need for prime-boost vaccine regimens.
5. Conclusions
Microneedle vaccines have traditionally exploited the naturally endowed immune-
functionality of the skin as a primary barrier to pathogen entry, however further
improvements to skin vaccination can be realized through the design of delivery approaches
which similarly mimic the natural time course of pathogen invasion, recognition, and
response. Here we have demonstrated the potency of this approach by designing a
microneedle delivery strategy capable of mimicking the extended kinetic profile for antigen
and adjuvant exposure following natural infection. Composite silk/PAA microneedles were
able to rapidly disintegrate after insertion into the skin releasing vaccine bolus from
dissolving PAA pedestals while simultaneously forming persistent cutaneous silk implants
to mediate the sustained low-level delivery of vaccine over time. The flexibility of this
approach for high-density loading and controllable release of biologically-sensitive vaccine
components allowed for programmable vaccine delivery in the skin to generate potent
cellular and humoral immunity superior to prime vaccination by hypodermic injection.
Notably, these responses were elicited following months of microneedle storage at room
temperature and gave equivalent immunity to those following prime-boost injection
regimens. This ability for potent immunity following a single immunization, combined with
the potential for long term room temperature storage, and safe needle-free administration
make this strategy an attractive option for effective global vaccine distribution, and
deployment.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Fabrication and in vitro characterization of silk/PAA composite microneedles. (a) Schematic
of microneedle fabrication: (1) PDMS molds were fabricated using laser ablation, (2) silk-
vaccine formulations were added to plasma treated molds and infiltrated into mold cavities
by centrifugation, (3) silk was drie d in mold cavities forming hardened tips and left
untreated or exposed to MeOH, (4) vaccine -loaded PAA was added to the mold and
infiltrated into mold cavities by centrifugation, and (5) arrays were dried before removal. (b)
Optical micrograph of silk/PAA microneedle array encapsulating AF647-OVA (blue) in silk
tips, and AF555-OVA (red) in PAA pedestals (scale bar - 500μm). (c) Confocal micrographs
of composite microneedles showing AF647-OVA (blue) in silk tips and AF555-OVA (red)
in PAA pedestals (scale bar - 500μm). (d) SEM micrographs of a separated silk tip
following 30 seconds exposure of a composite array to deionized water. Micrographs show
intact tip structure (left, scale bar - 500μm) and micro-porous silk hydrogel structure (center,
scale bar - 20μm, and right, scale bar - 5μm). (e) Quantitative analysis of fluorescent OVA
release from silk and PAA fractions of composite microneedles over time.
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Figure 2.
Composite microneedles deliver loaded vaccines to murine skin in vivo. (a) Confocal
micrographs of composite microneedles showing AF647-OVA (blue) in silk tips and
AF555-OVA (red) in PAA pedestals (scale bar - 500μm) before application (left) and
following a 5 minutes application to murine auricular skin (right). (b) Confocal micrographs
showing OVA delivery to murine skin following 5 minutes application of composite
microneedles (AF647-OVA in silk tips – blue, andAF555-OVA in PAA pedestals – red,
insertion sites outlined, scale bar - 500μm). (c) Confocal micrograph of histologically
sectioned skin treated for 5 minutes with composite microneedles (AF647-OVA in silk tips
– blue, andAF555-OVA in PAA pedestals – red, scale bar - 100μm). (d) Whole animal
fluorescent images of mice treated (arrows, right ear) with composite microneedles
containing AF647-OVA (blue) in silk tips (±MeOH treatment) and AF555-OVA (red) in
PAA pedestals. (e) Quantitative analysis of total fluorescent OVA signal measured at the
treatment site for mice receiving i.d. injection or microneedle delivery of AF647-OVA in
silk tips (±MeOH treatment) and AF555-OVA in PAA pedestals.
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Figure 3.
Prolonged vaccine release profile elicits increased proliferation of antigen-specific CD8+ T
cells. C57Bl/6 mice (n=5/group) were vaccinated on day 0 either by i.d. injection or
microneedle treatment (±MeOH to increase crystallinity of silk implants) with 9 μg OVA
and 150 ng polyI:C. Microneedles were fabricated with 98% of the total vaccine dose in the
PAA fraction, with the remaining 2% in the silk implant (MN PAA(98)/Silk(2) and MN
PAA(98)/MeOH-Silk(2)); control microneedles were fabricated with either 98% of the total
vaccine dose in the PAA (MN PAA(98)/Silk(0)) or 2% of the total dose in the silk fraction
(MN PAA(0)/Silk(2)). (a-c) Flow cytometry analysis of antigen-specific CD8+ T cell
proliferation in peripheral blood. Shown are (a) representative cytometry plots from day 14,
and (b-c) quantitative analysis of SIINFEKL-tetramer+ CD8+ T cell frequencies for 4 weeks
following vaccination. (b, * p<0.05 for MN PAA(98)/Silk(0) versus MN PAA(0)/Silk(2), #
p<0.05 for MN PAA(98)/Silk(0) and MN PAA(0)/Silk(2) versus i.d., c, * p<0.05 for MN
PAA(98)/MeOH-Silk(2) versus MN PAA(98)/MeOH-Silk(2), # p<0.05 for MN PAA(98)/
MeOH-Silk(2) and MN PAA(98)/Silk(2) versus i.d.). (d-e) Flow cytometry analysis of
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inflammatory cytokine expression following ex vivo antigen restimulation. Shown is
quantitative analysis of IFNγ+ and IFNγ+/TNFα+ CD8+ T cells measured on day 14. (*
p<0.05)
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Figure 4.
Microneedle vaccination gives enhanced memory CD8+ T-cell phenotypes compared to
traditional injections. C57Bl/6 mice (n=5/group) were vaccinated on day 0 either by i.d.
injection or microneedle treatment (±MeOH to cross-link silk implants) with 9 μg OVA and
150 ng polyI:C. Microneedles were fabricated with 98% of the total vaccine dose in the
PAA fraction, with the remaining 2% in the silk implant (MN PAA(98)/Silk(2) and MN
PAA(98)/MeOH-Silk(2)); control microneedles were fabricated with either 98% of the total
vaccine dose in the PAA (MN PAA(98)/Silk(0)) or 2% of the total dose in the silk fraction
(MN PAA(0)/Silk(2)). (a-b) Flow cytometry analysis of antigen-specific CD8+ T cell
memory phenotype in peripheral blood. Shown are (a) representative cytometry and (b)
quantitative analysis of CD44 and CD62L on SIINFEKL-tetramer+ CD8+ T cells on day 63
following vaccination. (c-e) Immunized mice were recalled (timeline, (c)) by i.m. injection
of 20 μg pOVA on day 77. Shown are (d) representative cytometry plots and (e) quantitative
analysis of IFNγ+ and IFNγ+/TNFα+ CD8+ T cells measured on day 91 following ex vivo
antigen restimulation of PBMCs (day 14 post recall).
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Figure 5.
Delivery method determines the strength and isotype balance of humoral responses
following i.d. or microneedle vaccination. C57Bl/6 mice (n=5/group) were immunized as in
Fig. 4. Shown are serum OVA-specific antibody titers and avidity indices measured on day
21. Serum OVA-specific antibody titers are shown for (a) IgM, (b) IgG, (c) IgG1, and (d)
IgG2C. (e) Avidity index for serum IgG , calculated as the ratio of titer measured without
urea pretreatment of bound serum to titer with urea pretreatment. (*p<0.05 compared to i.d.)
DeMuth et al. Page 20
Adv Healthc Mater. Author manuscript; available in PMC 2015 January 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 6.
Vaccine-releasing composite microneedles prolong local inflammation. (a) Whole animal
chemiluminescent images of mice treated (arrows, right ear) with composite microneedles
containing OVA and polyI:C in silk tips (±MeOH treatment) and PAA pedestals. Mice were
imaged following luminol administration to visualize MPO-dependent oxidative flux in
activated immune cells. (b) Quantitative analysis of total luminescent signal measured at the
treatment site for mice receiving i.d. injection or microneedle delivery of OVA and polyI:C
in silk tips (±MeOH treatment) and PAA pedestals. (* p<0.05 compared to baseline)
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